Explore how India's 20-year product patent regime transformed its pharma industry from generics to innovation, the economic ...

The Federal Circuit recently considered the scope of a permanent injunction that prohibited a drug manufacturer from ...

A new FDA application for vepdegestrant offers hope for advanced breast cancer patients with ESR1 mutations, showcasing ...

Vepdegestrant showed a benefit for patients with ER-positive, HER2-negative, ESR1-mutated breast cancer who had previously received endocrine-based therapy.

The development of innovative pharmaceuticals targeting refractory mental health conditions has stagnated for decades. In recent years, ...

Kura Oncology and Kyowa Kirin submitted data from the KOMET-001 trial, which the agency will review and decide whether to approve the drug by Nov. 30.

The company is one of the first to receive a “platform technology designation,” which could speed the review of certain gene ...

SHELTON, CT / ACCESS Newswire / June 4, 2025 / NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company ...

XP 8121 is a combination drug meant to better control hypothyroidism, in part by moving its common therapy, levothyroxine, ...

Tenpoint Therapeutics announced that the new drug application (NDA) for its presbyopia candidate, brimochol PF, has been ...

The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application (NDA) for ziftomenib as a treatment for adult patients with relapsed or refractory (R/R) acute myeloid ...

Kura Oncology won FDA priority review for its drug the day before announcing new data at ASCO 2025 showing remission in about ...